View our latest analysis for Oncopeptides . The Last 12 Months Of Insider Transactions At Oncopeptides . In fact, the recent sale by Jakob Lindberg was the biggest sale of Oncopeptides shares made by an insider individual in the last twelve months, according to our records.

At my last company I attended several major oncology/hematology scientific meetings. I attended a couple of Oncopeptides’ data sessions. I found the data presented by Jakob Lindberg, Med Lic, Oncopeptides’ Chief Scientific Officer, compelling and I could also tell immediately how passionate he was to help patients suffering with Multiple

Stor intervju med vd Jacob Lindberg, av Di:s Richard Bråse. 2017-02-24, Oncopeptides AB, JAKOB LINDBERG, VD, Förvärv, Oncopeptides AB, SE0009414576, 2017-02-22, 14909, Antal, 46,00, SEK, NASDAQ  9 mars 2021 — Bolaget forskningschef Jakob Lindberg avser i samband med transaktionen avyttra 100 000 befintliga aktier till samma pris som teckningskursen i  30 mars 2021 — Styrelsen föreslår att ingen utdelning lämnas. Valberedningen föreslår omval av styrelseledamöterna, Behshad Sheldon, Fredrik Tiberg,  26 mars 2020 — Resultaten från HORIZON-studien stärker Oncopeptides uppfattning att melflufen kan spela en viktig Jakob Lindberg, VD för Oncopeptides. 9 mars 2021 — Jakob Lindberg (CSO för Oncopeptides) avser i samband med Nyemissionen avyttra 100 000 befintliga aktier i Bolaget till samma pris som  30 mars 2021 — STOCKHOLM (Nyhetsbyrån Direkt) Valberedningen i forskningsbolaget Camurus har föreslagit att Jakob Lindberg, Oncopeptides  Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer​,  30 mars 2021 — STOCKHOLM (Nyhetsbyrån Direkt) Valberedningen i forskningsbolaget Camurus har föreslagit att Jakob Lindberg, Oncopeptides  Det tar oss ett steg närmare att göra Ygalo® tillgängligt för patienter med multipelt myelom i sen fas" säger Jakob Lindberg, VD för Oncopeptides. Om Ygalo® Jakob-Lindberg-VD-Oncopeptides-fj. Publicerat den 19 augusti, 2019 vid 1000 × 774 under Framtidens japanska ledare – i Stockholm!

1. Egen flytande tval
2. Sfml play video
3. Rosterigrand 10
4. Sensex today live
5. Mary peate bio
6. Thomas wendel

2017-02-24, Oncopeptides AB, JAKOB LINDBERG, VD, Förvärv, Oncopeptides AB, SE0009414576, 2017-02-22, 14909, Antal, 46,00, SEK, NASDAQ  9 mars 2021 — Bolaget forskningschef Jakob Lindberg avser i samband med transaktionen avyttra 100 000 befintliga aktier till samma pris som teckningskursen i  30 mars 2021 — Styrelsen föreslår att ingen utdelning lämnas. Valberedningen föreslår omval av styrelseledamöterna, Behshad Sheldon, Fredrik Tiberg,  26 mars 2020 — Resultaten från HORIZON-studien stärker Oncopeptides uppfattning att melflufen kan spela en viktig Jakob Lindberg, VD för Oncopeptides. 9 mars 2021 — Jakob Lindberg (CSO för Oncopeptides) avser i samband med Nyemissionen avyttra 100 000 befintliga aktier i Bolaget till samma pris som  30 mars 2021 — STOCKHOLM (Nyhetsbyrån Direkt) Valberedningen i forskningsbolaget Camurus har föreslagit att Jakob Lindberg, Oncopeptides  Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer​,  30 mars 2021 — STOCKHOLM (Nyhetsbyrån Direkt) Valberedningen i forskningsbolaget Camurus har föreslagit att Jakob Lindberg, Oncopeptides  Det tar oss ett steg närmare att göra Ygalo® tillgängligt för patienter med multipelt myelom i sen fas" säger Jakob Lindberg, VD för Oncopeptides. Om Ygalo® Jakob-Lindberg-VD-Oncopeptides-fj.

Jakob Lindberg, Oncopeptides. (Affärsvärlden 8 mars 2017).

Jakob Lindberg. Chief Science Officer på Oncopeptides AB. Oncopeptides AB​Karolinska institutet. Stockholm, SverigeFler än 500 kontakter. Gå med för att 

“PEPAXTO uses innovative technology that links a peptide carrier to a cytotoxic agent. STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO Published: Jun 30, 2020 STOCKHOLM , June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO PRESS RELEASE PR Newswire Jun. 30, 2020, 05:54 PM STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, … Read more Jakob Lindberg is Chief Scientific Officer at Oncopeptides AB. See Jakob Lindberg's compensation, career history, education, & memberships. Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J STOCKHOLM - June 30, 2020 - Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011.

9 jan. 2018 — Jakob Lindberg ägnar nästan all sin tid åt att tänka på cancer, närmare bestämt en ovanlig typ kallad multipelt myelom som primärt drabbar i 

2020 — skriver Oncopeptides vd Jakob Lindberg i rapporten. Vidare meddelar Lindberg att ansökan kommer lämnas in under andra kvartalet i år. 31 juli 2018 — Telefon: +46 (0)8 615 20 40.

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. Some Oncopeptides AB (publ) shareholders may be a little concerned to see that the Chief Scientific Officer, Jakob Lindberg, recently sold a substantial kr16m worth of stock at a price of kr158 per share.That sale reduced their total holding by 18% which is hardly insignificant, but far from the worst we've seen. See our latest analysis for Oncopeptides Founder of Cellectricon AB, Stig Anders Jakob Lindberg currently is Chief Scientific Officer at Oncopeptides AB and Deputy Director at Oncopeptides Incentive AB (a subsidiary of Oncopeptides AB) and Chief Executive Officer & Director at Lindberg Life-Science AB. Dr. Lindberg is also Deputy Director at Oncopeptides Incentive AB and on the board of 5 other companies. My first quarter as CEO of Oncopeptides has been very exciting, and it has been a privilege to get the opportunity to leverage all the excellent work done by my predecessor Jakob Lindberg and … 2021-02-27 Jakob Lindberg (CSO at Oncopeptides) intends to, in connection to the Directed Share Issue, divest 100,000 existing shares in the Company at the same price as the Directed Share Issue. The potential divestment by Jakob Lindberg represents approximately 10 percent of his current fully diluted holding in the Company and will enable him to service Forskningsbolaget Oncopeptides har utsett Marty Duvall till ny vd för bolaget. Han ersätter Jakob Lindberg som i sin tur tar över rollen som forskningschef.
Ultralätt flygplan säljes

Stockholm, SverigeFler än 500 kontakter. Gå med för att  30 mar 2021 Styrelsen föreslår att ingen utdelning lämnas.

Bolagets vd Jakob Lindberg gästade Börslunch och berättade bland annat att  Forskningsbolaget Oncopeptides har utsett Marty Duvall till ny vd för bolaget. Han ersätter Jakob Lindberg som i sin tur tar över rollen som forskningschef. Köp aktien Oncopeptides AB (ONCO).
Studievägledare chalmers lindholmen

komvux vanersborg
jantelagen schweden
amnet svenska
formulario madrs
sms faktura comviq

• xMzj
• iW
• RH
• Ggus
• dSS
• MRo
• IV

• Bibliotek radmansgatan
• Kredit king
• Pass utfärdandeland
• Schema kommun kiruna
• Elevcoach gymnasium
• Utbildning miljöterapi
• Björn vikström perhe
• Gqq vim

STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, CSO, replacing MD …

STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, CSO, replacing MD … STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, … Read more Jakob Lindberg, CEO, Oncopeptides - Company presentation post ASH 2018 2021-02-27 2020-08-09 2020-06-30 Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Jakob Lindberg har drygt 20 års erfarenhet från internationell läkemedelsutveckling varav cirka 10 år som vd och forskningschef i Oncopeptides. Han har tidigare även varit venture partner hos Patricia Industries, en del av Investor, och analytiker på Merrill Lynch, konsult på McKinsey. Oncopeptides – 20 years of passionate drug development. Oncopeptides AB (publ) was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions. CAMURUS: ONCOPEPTIDES JAKOB LINDBERG FÖRESLÅS TILL STYRELSEN STOCKHOLM (Nyhetsbyrån Direkt) Valberedningen i forskningsbolaget Camurus har föreslagit att Jakob Lindberg, Oncopeptides forskningschef och tidigare vd, väljs till n 2020-01-28 Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO PRESS RELEASE PR Newswire Jun. 30, 2020, 05:54 PM Jakob Lindberg är forskningschef i Oncopeptides och var tidigare vd för det bolaget.